Cargando…

Influence of immunosuppressive therapy on longitudinal changes in anti-SARS-CoV-2 spike protein antibodies after two doses of mRNA vaccines in patients with rheumatic diseases

Detalles Bibliográficos
Autores principales:	Kawazoe, Mai, Aoki, Kotaro, Hirose, Wataru, Masuoka, Shotaro, Nanki, Toshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Federation of Internal Medicine. Published by Elsevier B.V. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083199/ https://www.ncbi.nlm.nih.gov/pubmed/37045711 http://dx.doi.org/10.1016/j.ejim.2023.04.008

Ejemplares similares

Safety of SARS-CoV-2 mRNA vaccines and effects of immunosuppressive drugs on adverse reactions in patients with rheumatic diseases
por: Kawazoe, Mai, et al.
Publicado: (2023)

Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases
por: Kaneko, Kaichi, et al.
Publicado: (2022)

Apparent Hypothalamic-Pituitary-Adrenal Axis Suppression via Reduction of Interleukin-6 by Glucocorticoid Therapy in Systemic Autoimmune Diseases
por: Fujio, Natsuki, et al.
Publicado: (2016)

Methotrexate-associated lymphoproliferative disorders in the central nervous system and stomach: A case report
por: Kawazoe, Mai, et al.
Publicado: (2020)

Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists
por: Kawazoe, Mai, et al.
Publicado: (2021)

Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases
por: Tanaka, Nahoko, et al.
Publicado: (2016)

Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
por: Nanki, Toshihiro, et al.
Publicado: (2022)

Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial　tissues of rheumatoid arthritis
por: Masuoka, Shotaro, et al.
Publicado: (2018)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

Treatment with an Anti-CX3CL1 Antibody Suppresses M1 Macrophage Infiltration in Interstitial Lung Disease in SKG Mice
por: Mizutani, Satoshi, et al.
Publicado: (2021)

Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Diagnostic performance of measuring antibodies to the glycopeptidolipid core antigen specific to Mycobacterium avium complex in patients with rheumatoid arthritis: results from a cross-sectional observational study
por: Hirose, Wataru, et al.
Publicado: (2015)

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2021)

Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2022)

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
por: Frey, Sarah, et al.
Publicado: (2022)

Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis
por: Yamamoto, Tatsuhiro, et al.
Publicado: (2016)

Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy
por: Cosan, Fulya, et al.
Publicado: (2023)

COVID-19 in rheumatic disease patients on immunosuppressive agents
por: Sharmeen, Saika, et al.
Publicado: (2020)

A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases
por: Patil, Abhishek, et al.
Publicado: (2022)

Resistin upregulates chemokine production by fibroblast-like synoviocytes from patients with rheumatoid arthritis
por: Sato, Hiroshi, et al.
Publicado: (2017)

Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination
por: Frey, Sarah, et al.
Publicado: (2021)

Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine
por: Debes, Amanda K., et al.
Publicado: (2022)

Is it safe to vaccinate rheumatic immunosuppressed patients? Yes, of course, but how?
por: Gillet, Pierre
Publicado: (2021)

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy
por: Sugihara, Koichi, et al.
Publicado: (2022)

The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients
por: Fiorino, Fabio, et al.
Publicado: (2022)

Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry
por: Kihara, Mari, et al.
Publicado: (2022)

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence
por: Venerito, Vincenzo, et al.
Publicado: (2020)

Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
por: Quiroga, Borja, et al.
Publicado: (2022)

Serum Anti-Spike Antibodies Are Not Affected by Immunosuppressants in SARS-CoV-2 Vaccinations Given to Brazilian Patients with Inflammatory Bowel Disease
por: Pereira, Magno Luís Costa, et al.
Publicado: (2023)

Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease
por: Frommert, Leonie Maria, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients
por: Mitchell, Jonathan, et al.
Publicado: (2022)

Predictors of low spike antibody response in patients with systemic rheumatic disease after an initial course of COVID-19 vaccination
por: Whelan, Mary Grace, et al.
Publicado: (2023)

Longitudinal Comparison of Neutralizing Antibody Responses to COVID-19 mRNA Vaccines after Second and Third Doses
por: Roeder, Alexa J., et al.
Publicado: (2022)

Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
por: Stellini, Roberto, et al.
Publicado: (2022)

SARS-CoV-2-Spike Antibody and T-Cell Responses Elicited by a Homologous Third mRNA COVID-19 Dose in Hemodialysis and Kidney Transplant Recipients
por: Panizo, Nayara, et al.
Publicado: (2022)

Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein
por: Otsubo, Ryota, et al.
Publicado: (2022)

De novo Emergence of SARS-CoV-2 Spike Mutations in Immunosuppressed Patients
por: Simons, Lacy M., et al.
Publicado: (2022)

Retrospective study on the effects of immunosuppressive therapy in uveitis associated with rheumatic diseases in Korea
por: Lee, Sang Yeob, et al.
Publicado: (2011)

Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria
por: Rebholz, Heike, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_56s9m2vninsnksbdr8kltg8or6